EGFR and breast carcinoma: Treatment of breast cancer cells with a combination of Her-1 and Her-2 inhibitors results in a synergistic antitumor effect mediated by the modulation of several downstream signaling proteins and cell cycle regulatory proteins, including transcriptional and posttranscriptional regulation of p27 expression [12].